Buzz
The FDA has recently approved a new COVID vaccine named Novavax, with the government securing 3.2 million doses. This introduces a fourth vaccination option against COVID. What exactly is Novavax, its effectiveness, and who should opt for it?
Similar to the Pfizer vaccine, Novavax requires two doses administered three weeks apart. It's approved for individuals aged 18 and above, and the manufacturer is currently developing a booster and a pediatric version. The FDA has granted Novavax an emergency use authorization (EUA), akin to other COVID vaccines at their initial release. The CDC's recommendation is pending, with availability expected shortly after approval, anticipated next week. [Update: the CDC endorsed it on July 20.]
What distinguishes Novavax from other COVID-19 vaccines?
The primary distinction lies in the vaccine's mechanism. Currently, we have two mRNA-based vaccines (Pfizer and Moderna) and one DNA-based vaccine (Johnson & Johnson). Novavax, however, employs a protein-based approach.
Each vaccine stimulates our immune system to produce antibodies targeting the coronavirus's spike protein. The mRNA vaccines provide RNA-based instructions for our cells to produce the protein, prompting an immune response. The Johnson & Johnson vaccine uses DNA instructions, delivered via a deactivated cold virus.
In contrast, Novavax directly introduces the spike protein, combined with an adjuvant derived from the soapbark tree. (Adjuvants boost immune responses and are common in many non-COVID vaccines.) Production was slower due to the need to manufacture spike proteins using insect cells (no insect remnants remain in the final product). This method is akin to that used for certain flu vaccines.
Why might someone choose Novavax over Pfizer or Moderna?
In the U.S., the reasons are limited. However, if mRNA technology concerns have delayed your vaccination (despite its proven safety), Novavax offers a more traditional vaccine approach. Additionally, it may suit those allergic to ingredients in other vaccines, as its composition differs.
The safety and effectiveness of the Novavax vaccine appear comparable to other COVID vaccines. Typical side effects, such as fatigue and arm soreness, are similar, as are the rare risks of severe reactions like myocarditis or anaphylaxis in cases of ingredient allergies.
In regions with limited access to mRNA vaccines or challenges in maintaining ultra-cold storage, Novavax offers a practical alternative. Its storage requirements are simpler, needing only refrigerator temperatures.
Ultimately, Novavax is simply another vaccination option. If available, it’s a viable choice. However, most individuals seeking COVID vaccines have already been vaccinated, making its current relevance limited. Future interest may arise with updated boosters, but data on their performance remains pending.
